{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Cancer%2C+Treatment-Related&page=5", "query": { "condition": "Cancer, Treatment-Related", "page": 5 }, "page_size": 10 }, "pagination": { "page": 5, "page_size": 10, "total_count": 926, "total_pages": 93, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Cancer%2C+Treatment-Related&page=6&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Cancer%2C+Treatment-Related&page=4&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-04T05:20:58.155Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT04305145", "title": "Infliximab for Treatment of Immune Checkpoint Inhibitor Colitis", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Melanoma Stage III", "Melanoma Stage IV", "Skin Cancer Stage III", "Skin Cancer Stage IV", "Drug-Induced Colitis", "Drug Toxicity", "Immune-related Adverse Event" ], "interventions": [ { "name": "Infliximab", "type": "DRUG" }, { "name": "Methylprednisolone", "type": "DRUG" }, { "name": "Prednisone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Massachusetts General Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 42, "start_date": "2020-08-31", "completion_date": "2030-06-30", "has_results": false, "last_update_posted_date": "2026-06-16", "last_synced_at": "2026-10-04T05:20:58.155Z", "location_count": 2, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT04305145" }, { "nct_id": "NCT05973487", "title": "A Basket Study of Customized Autologous TCR-T Cell Therapies in Patients With Locally Advanced (Unresectable) or Metastatic Solid Tumors", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Head and Neck Cancer", "Cervical Cancer", "Non-small Cell Carcinoma", "Melanoma", "Ovarian Cancer", "Anogenital Cancers", "HPV - Anogenital Human Papilloma Virus Infection", "HPV-Related Cervical Carcinoma", "HPV-Related Carcinoma", "HPV-Related Squamous Cell Carcinoma", "HPV-Related Malignancy", "HPV-Related Adenocarcinoma", "HPV Positive Oropharyngeal Squamous Cell Carcinoma", "HPV-Related Adenosquamous Carcinoma", "HPV-Associated Vaginal Adenocarcinoma", "HPV-Related Endocervical Adenocarcinoma", "HPV-Related Anal Squamous Cell Carcinoma", "HPV-Related Verrucous Carcinoma", "HPV-Related Penile Squamous Cell Carcinoma", "HPV-Related Vulvar Squamous Cell Carcinoma", "HPV Positive Rectal Squamous Cell Carcinoma" ], "interventions": [ { "name": "TSC-204-A0201", "type": "BIOLOGICAL" }, { "name": "TSC-204-C0702", "type": "BIOLOGICAL" }, { "name": "TSC-200-A0201", "type": "BIOLOGICAL" }, { "name": "TSC-204-A0201 + TSC-204-C0702", "type": "BIOLOGICAL" }, { "name": "TSC-204-A0201 + TSC-200-A0201", "type": "BIOLOGICAL" }, { "name": "TSC-204-C0702 + TSC-200-A0201", "type": "BIOLOGICAL" }, { "name": "TSC-204-A0201 + TSC-203-A0201", "type": "BIOLOGICAL" }, { "name": "TSC-204-C0702 + TSC-203-A0201", "type": "BIOLOGICAL" }, { "name": "TSC-200-A0201 + TSC-203-A0201", "type": "BIOLOGICAL" }, { "name": "TSC-203-A0201", "type": "BIOLOGICAL" }, { "name": "TSC-204-A0101", "type": "BIOLOGICAL" }, { "name": "TSC-201-B0702", "type": "BIOLOGICAL" }, { "name": "TSC-204-A0201 + TSC-204-A0101", "type": "BIOLOGICAL" }, { "name": "TSC-204-A0201 + TSC-201-B0702", "type": "BIOLOGICAL" }, { "name": "TSC-204-C0702 + TSC-204-A0101", "type": "BIOLOGICAL" }, { "name": "TSC-204-C0702 + TSC-201-B0702", "type": "BIOLOGICAL" }, { "name": "TSC-200-A0201 + TSC-204-A0101", "type": "BIOLOGICAL" }, { "name": "TSC-200-A0201 + TSC-201-B0702", "type": "BIOLOGICAL" }, { "name": "TSC-203-A0201 + TSC-204-A0101", "type": "BIOLOGICAL" }, { "name": "TSC-203-A0201 + TSC-201-B0702", "type": "BIOLOGICAL" }, { "name": "TSC-202-A0201", "type": "BIOLOGICAL" }, { "name": "TSC-204-A0201 + TSC-202-A0201", "type": "BIOLOGICAL" }, { "name": "TSC-204-C0702 + TSC-202-A0201", "type": "BIOLOGICAL" }, { "name": "TSC-200-A0201 + TSC-202-A0201", "type": "BIOLOGICAL" }, { "name": "TSC-203-A0201 + TSC-202-A0201", "type": "BIOLOGICAL" }, { "name": "TSC-204-A0101 + TSC-202-A0201", "type": "BIOLOGICAL" }, { "name": "TSC-201-B0702 + TSC-202-A0201", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "TScan Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 840, "start_date": "2024-05-06", "completion_date": "2026-12-30", "has_results": false, "last_update_posted_date": "2025-11-17", "last_synced_at": "2026-10-04T05:20:58.155Z", "location_count": 21, "location_summary": "Scottsdale, Arizona • San Diego, California • New Haven, Connecticut + 17 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "San Diego", "state": "California" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Hollywood", "state": "Florida" }, { "city": "Miami", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT05973487" }, { "nct_id": "NCT00750009", "title": "Personalized Information or Basic Information in Helping Patients Make Decisions About Participating in a Clinical Trial", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Brain and Central Nervous System Tumors", "Chronic Myeloproliferative Disorders", "Leukemia", "Lymphoma", "Lymphoproliferative Disorder", "Multiple Myeloma and Plasma Cell Neoplasm", "Myelodysplastic Syndromes", "Myelodysplastic/Myeloproliferative Neoplasms", "Unspecified Adult Solid Tumor, Protocol Specific" ], "interventions": [ { "name": "educational intervention", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "Case Comprehensive Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "120 Years", "sex": "ALL", "summary": "18 Years to 120 Years" }, "enrollment_count": 583, "start_date": "2008-04", "completion_date": "2012-12", "has_results": false, "last_update_posted_date": "2020-07-27", "last_synced_at": "2026-10-04T05:20:58.155Z", "location_count": 4, "location_summary": "Detroit, Michigan • Cleveland, Ohio • Philadelphia, Pennsylvania", "locations": [ { "city": "Detroit", "state": "Michigan" }, { "city": "Cleveland", "state": "Ohio" }, { "city": "Cleveland", "state": "Ohio" }, { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT00750009" }, { "nct_id": "NCT00049634", "title": "Donor Peripheral Stem Cell Transplant in Treating Patients With Myelodysplastic Syndrome, Acute Myeloid Leukemia, or Myeloproliferative Disorder", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Chronic Myeloproliferative Disorders", "Leukemia", "Myelodysplastic Syndromes", "Myelodysplastic/Myeloproliferative Diseases" ], "interventions": [ { "name": "busulfan", "type": "DRUG" }, { "name": "cyclophosphamide", "type": "DRUG" }, { "name": "cyclosporine", "type": "DRUG" }, { "name": "methotrexate", "type": "DRUG" }, { "name": "in vitro-treated peripheral blood stem cell transplantation", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "Fred Hutchinson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 30, "start_date": "2002-01", "completion_date": null, "has_results": false, "last_update_posted_date": "2010-09-16", "last_synced_at": "2026-10-04T05:20:58.155Z", "location_count": 2, "location_summary": "Seattle, Washington", "locations": [ { "city": "Seattle", "state": "Washington" }, { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT00049634" }, { "nct_id": "NCT04552704", "title": "CD24Fc for the Treatment of Immune Related Adverse Events in Patients With Advanced Solid Tumors, TIRAEC Study", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Advanced Malignant Solid Neoplasm" ], "interventions": [ { "name": "CD24 Extracellular Domain-IgG1 Fc Domain Recombinant Fusion Protein CD24Fc", "type": "BIOLOGICAL" }, { "name": "Placebo Administration", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Tianhong Li", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 3, "start_date": "2020-10-30", "completion_date": "2022-01-26", "has_results": true, "last_update_posted_date": "2026-08-10", "last_synced_at": "2026-10-04T05:20:58.155Z", "location_count": 1, "location_summary": "Sacramento, California", "locations": [ { "city": "Sacramento", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04552704" }, { "nct_id": "NCT00477607", "title": "Alpha-Lipoic Acid in Preventing Hearing Loss in Cancer Patients Undergoing Treatment With Cisplatin", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Ototoxicity", "Unspecified Adult Solid Tumor" ], "interventions": [ { "name": "alpha-lipoic acid", "type": "DRUG" }, { "name": "Audiology", "type": "BEHAVIORAL" }, { "name": "laboratory biomarker analysis", "type": "BIOLOGICAL" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG", "BEHAVIORAL", "BIOLOGICAL" ], "sponsor": "US Department of Veterans Affairs", "sponsor_class": "FED", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 39, "start_date": "2007-10", "completion_date": "2011-06", "has_results": true, "last_update_posted_date": "2014-03-07", "last_synced_at": "2026-10-04T05:20:58.155Z", "location_count": 2, "location_summary": "Portland, Oregon", "locations": [ { "city": "Portland", "state": "Oregon" }, { "city": "Portland", "state": "Oregon" } ], "official_url": "https://clinicaltrials.gov/study/NCT00477607" }, { "nct_id": "NCT00414024", "title": "Safety and Efficacy of Tegaserod in Opioid-induced Constipation in Patients With Non-cancer Pain.", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Opioid-induced Constipation" ], "interventions": [ { "name": "Tegaserod", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis", "sponsor_class": "INDUSTRY", "healthy_volunteers": null, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 11, "start_date": "2007-02", "completion_date": "2007-05", "has_results": false, "last_update_posted_date": "2012-04-20", "last_synced_at": "2026-10-04T05:20:58.155Z", "location_count": 1, "location_summary": "East Hanover, New Jersey", "locations": [ { "city": "East Hanover", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT00414024" }, { "nct_id": "NCT03451773", "title": "M7824 (MSB0011359C) in Combination With Gemcitabine in Adults With Previously Treated Advanced Adenocarcinoma of the Pancreas", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Cancer of Pancreas", "Pancreas Cancer", "Pancreatic Adenocarcinoma", "Pancreatic Cancer", "Pancreatic Neoplasms" ], "interventions": [ { "name": "M7824", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 7, "start_date": "2018-05-17", "completion_date": "2020-05-05", "has_results": true, "last_update_posted_date": "2021-06-16", "last_synced_at": "2026-10-04T05:20:58.155Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT03451773" }, { "nct_id": "NCT02270983", "title": "Phase 2 Randomized, Double-Blind, Placebo-Controlled, Parallel Group Trial of Linaclotide Administered to Patients With Opioid-Induced Constipation Receiving Chronic Opioid Treatment for Non-Cancer Pain", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Opioid-Induced Constipation" ], "interventions": [ { "name": "Linaclotide 145 micrograms", "type": "DRUG" }, { "name": "Linaclotide 290 micrograms", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Forest Laboratories", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 254, "start_date": "2014-10-31", "completion_date": "2015-10-31", "has_results": true, "last_update_posted_date": "2019-04-08", "last_synced_at": "2026-10-04T05:20:58.155Z", "location_count": 77, "location_summary": "Anniston, Alabama • Foley, Alabama • Phoenix, Arizona + 67 more", "locations": [ { "city": "Anniston", "state": "Alabama" }, { "city": "Foley", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "North Little Rock", "state": "Arkansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02270983" }, { "nct_id": "NCT04095273", "title": "Study to Test How Well Patients With Advanced Solid Tumors Respond to Treatment With the Elimusertib in Combination With Pembrolizumab, to Find the Optimal Dose for Patients, How the Drug is Tolerated and the Way the Body Absorbs, Distributes and Discharges the Drug", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Solid Tumors" ], "interventions": [ { "name": "Elimusertib (BAY1895344)", "type": "DRUG" }, { "name": "Pembrolizumab (Keytruda®)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bayer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 56, "start_date": "2019-09-30", "completion_date": "2023-04-11", "has_results": false, "last_update_posted_date": "2024-04-02", "last_synced_at": "2026-10-04T05:20:58.155Z", "location_count": 8, "location_summary": "Palo Alto, California • New Haven, Connecticut • Baltimore, Maryland + 5 more", "locations": [ { "city": "Palo Alto", "state": "California" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT04095273" } ] }